… of life improvement in LUX-Lung 8, an open-label phase III study of second-line afatinib
versus erlotinib in patients with advanced squamous cell carcinoma of the lung after first-line …

… testing can predict outcome to erlotinib [7–9], … retrospective analysis of the LUX‐lung 8 study
demonstrated that VeriStrat could also predict OS in patients with squamous cell carcinoma …

… with erlotinib could improve PFS compared with erlotinib treatment alone as … retrospective
study revealed that anlotinib was well tolerated and effective in patients with advanced NSCLC …

… Because our study is a retrospective study with a small sample size, a large-sample
prospective study is needed to confirm the relationship between adverse reactions and the …

… retrospectively collected and analyzed the data of patients who had been confirmed advanced
lung … All information of these patients was identified from our electronic medical records …

… novel agent ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV …
This study was a two-center retrospective study with a limited number of included patients, …

… A retrospective study was conducted on 150 patients with advanced NSCLC who were
treated with anlotinib and discontinued treatment after disease progression or intolerance due to …

… patients when treated with chemotherapy compared to TKIs [16]. A recent retrospective study
in 119 patients with advanced NSCLC … OS and PFS compared with patients who did not …

… the EGFR unselected or EGFR wild-type patients, erlotinib as third-line treatment has been
… of our study should be recognized. The major limitation is its retrospective study. Because of …

… A retrospective study was conducted on 206 patients with … In the present study, we conducted
a retrospective study to assess the efficacy and toxicity of anlotinib in advanced NSCLC in …